AHR over-expression in papillary thyroid carcinoma: Clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Mian, Caterina ^a   Ceccato, Filippo ^a   Barollo, Susi ^a   Watutantrige Fernando, Sara ^a   Albiger, Nora ^a   Regazzo, Daniela ^a   De Lazzari, Paola ^a   Pennelli, Gianmaria ^a   Rotondi, Sandra ^b   Nacamulli, Davide ^a   Pelizzo, Maria Rosa ^a   Jaffrain Rea, Marie Lise ^b   Grimaldi, Franco ^c   Occhi, Gianluca ^a   Scaroni, Carla ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; B RAF KINASE; GROWTH HORMONE; IODINE; K RAS PROTEIN; SOMATOMEDIN C; AHR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BRAF PROTEIN, HUMAN;

ABLATION THERAPY; ACROMEGALY; ADULT; AGED; AIP GENE; ARTICLE; BRAF GENE; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GOITER; GROWTH HORMONE BLOOD LEVEL; H RAS GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; K RAS GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTINODULAR GOITER; N RAS GENE; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; UNINODULAR GOITER; VERY ELDERLY; CARCINOMA; COMPLICATION; GENETICS; ITALY; METABOLISM; MISSENSE MUTATION; THYROID NEOPLASMS; UPREGULATION; YOUNG ADULT;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, ARYL HYDROCARBON; THYROID NEOPLASMS; UP-REGULATION; YOUNG ADULT;

EID: 84904256173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101560     Document Type: Article

References (39)

1. Melmed S (2006) Medical Progress: Acromegaly. N Engl J Med 355: 2558-2573.
2. Colao AM, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152. (Pubitemid 38269977)
3. Kurimoto M, Fukuda I, Hizuka N, Takano K (2008) The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J 55: 67-71. (Pubitemid 351520181)
4. Ceccato F, Occhi G, Albiger NM, Rizzati S, Ferasin S, et al. (2011) Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. J Endocrinol Invest 34: 353-360.
5. Jenkins PJ, Mukherjee A, Shalet SM (2006) Does growth hormone cause cancer? Clin Endocrinol 64: 115-121.
6. Loeper S, Ezzat S (2008) Acromegaly: re-thinking the cancer risk. Rev Endoc Metab Disor 9: 41-58.
7. Colao AM, Pivonello R, Auriemma RS, Galdiero M, Ferone D, et al. (2007) The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. J Clin Endocrinol Metab 92: 3854-3860. (Pubitemid 47607633)
8. Duong CV, Emes RD, Wessely F, Yacqub-Usman K, Clayton RN, et al. (2012) Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas. Endocr Relat Cancer 19: 805-816.
9. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 83: 2730-2734. (Pubitemid 28493768)
10. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, et al. (1998) Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol 49: 441-445. (Pubitemid 28475335)
11. Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, et al. (2002) Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 25: 240-245. (Pubitemid 34295879)
12. Herrmann BL, Baumann H, Janssen OE, Görges R, Schmid KW, et al. (2004) Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes. 112: 225-230. (Pubitemid 38679265)
13. Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, et al. (2005) High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol 63: 161-167. (Pubitemid 41097984)
14. Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary. 13: 242-248.
15. Bałdys-Waligórska A, Krzentowska A, Gołkowski F, Sokołowski G, Hubalewska-Dydejczyk A (2010) The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol. 61: 29-34.
16. Dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, et al. (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary. 16: 109-114.
17. Dagdelen S, Cinar N, Erbas T (2013) Increased thyroid cancer risk in acromegaly. Pituitary. Jul 9. E-pub ahead of print. doi:10.1007/s11102-013-0501- 5.
18. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, et al. (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312: 1228-1230. (Pubitemid 43801151)
19. Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34: 239-277.
20. Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103: 15558-15563.
21. Raitila A, Georgitsi M, Karhu A, Tuppurainen K, Makinen MJ, et al. (2007) No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer 14: 901-906. (Pubitemid 350074077)
22. Raitila A, Georgitsi M, Bonora E, Vargiolu M, Tuppurainen K, et al. (2009) Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer. J Endocrinol Invest 32: 426-429.
23. Occhi G, Trivellin G, Ceccato F, De Lazzari P, Giorgi G, et al. (2010) Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol 163: 369-376.
24. Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, et al. (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16: 1029-1043.
25. Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, et al. (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer, 20, 753-766.
26. Watutantrige-Fernando S, Barollo S, Nacamulli D, Pozza D, Giachetti M, et al. (2013) Iodine status in schoolchildren living in northeast Italy: the importance of iodized salt use and milk consumption. Eur J Clin Nutr 67: 366-370.
27. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, et al. (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95: 3141-3148.
28. Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, et al. (2011) BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 21: 1393-1396.
29. Pardi E, Marcocci C, Borsari S, Saponaro F, Torregrossa L, et al. (2013) Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations Occur Rarely in Sporadic Parathyroid Adenomas. J Clin Endocrinol Metab 98: 2800-2810.
30. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49, 1374-1403.
31. Reiners C (2014) Thyroid cancer in 2013: Advances in our understanding of differentiated thyroid cancer. Nat Rev Endocrinol, 10: 69-70.
32. Roger P, Taton M, Van Sande J, Dumont JE (1998) Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 66: 1158-1165.
33. Onoda N, Ohmura E, Tsushima T, Ohba Y, Emoto N, et al. (1992) Autocrine role of insulin-like growth factor (IGF)-I in a human thyroid cancer cell line. Eur J Cancer 28: 1904-1909.
34. Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, et al. (1989) Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab 68: 621-686.
35. Hahn ME, Allan LL, Sherr DH (2009) Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor. Biochem Pharmacol 77: 485-497.
36. Tan Z, Chang X, Puga A, Xia Y (2002) Activation of mitogen-activated protein kinases (MAPKs) by aromatic hydrocarbons: role in the regulation of aryl hydrocarbon receptor (AHR) function. Biochem Pharmacol 64: 771-80. (Pubitemid 35232250)
37. Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, et al. (2014) Prevalence, Tumorigenic Role, and Biochemical Implications of Rare BRAF Alterations. Thyroid [Epub ahead of print].
38. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214.
39. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, et al. (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16: 294-302.